| Year |
Citation |
Score |
| 2022 |
Davdison SM, Schmidt DR, Heyman JE, O'Brien JP, Liu AC, Israelsen WJ, Dayton TL, Sehgal R, Bronson RT, Freinkman E, Mak HH, Fanelli GN, Malstrom S, Bellinger G, Carracedo A, ... ... Courtney KD, et al. Pyruvate kinase M1 suppresses development and progression of prostate adenocarcinoma. Cancer Research. PMID 35584006 DOI: 10.1158/0008-5472.CAN-21-2352 |
0.615 |
|
| 2019 |
Brugarolas J, Courtney KD, Ma Y, Diaz de Leon A, Christie A, Xie Z, Woolford L, Singla N, Joyce A, Hill H, Madhuranthakam AJ, Yuan Q, Xi Y, Zhang Y, Chang J, et al. HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor in Clear Cell Renal Cell Carcinoma Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31727677 DOI: 10.1158/1078-0432.Ccr-19-1459 |
0.328 |
|
| 2019 |
Desai NB, Courtney K, Subramaniam RM, Cadeddu JA. Salvage Radiotherapy for Nodal Oligorecurrent Prostate Cancer: A Step Towards Predictive Criteria for Metastasis-Directed Therapy in Prostate Cancer? European Urology. PMID 31421942 DOI: 10.1016/J.Eururo.2019.07.050 |
0.305 |
|
| 2019 |
Zhang Y, Schoenhals J, Christie A, Mohamad O, Wang C, Bowman I, Singla N, Hammers H, Courtney K, Bagrodia A, Margulis V, Desai N, Garant A, Choy H, Brugarolas J, et al. Stereotactic Ablative Radiotherapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 31377159 DOI: 10.1016/J.Ijrobp.2019.07.023 |
0.306 |
|
| 2019 |
Zhang Y, Schoenhals J, Christie A, Wang C, Mohamad O, Singla N, Desai N, Choy H, Courtney KD, Bagrodia A, Margulis V, Bowman IA, Timmerman RD, Brugarolas J, Hannan R. Outcomes of stereotactic ablative radiotherapy for extra-cranial oligo-metastatic renal cell cancer. Journal of Clinical Oncology. 37: 599-599. DOI: 10.1200/Jco.2019.37.7_Suppl.599 |
0.318 |
|
| 2018 |
Courtney KD, Bezwada D, Mashimo T, Pichumani K, Vemireddy V, Funk AM, Wimberly J, McNeil SS, Kapur P, Lotan Y, Margulis V, Cadeddu JA, Pedrosa I, DeBerardinis RJ, Malloy CR, et al. Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo. Cell Metabolism. PMID 30146487 DOI: 10.1016/J.Cmet.2018.07.020 |
0.312 |
|
| 2018 |
Kobayashi M, Chung JS, Beg M, Arriaga Y, Verma UN, Courtney K, Mansour JC, Haley B, Khan SA, Horiuchi Y, Ramani V, Harker D, Gopal P, Araghizadeh F, Cruz PD, et al. Blocking monocytic myeloid-derived suppressor cell function via anti-DC-HIL/GPNMB antibody restores the in vitro integrity of T-cells from cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30049749 DOI: 10.1158/1078-0432.Ccr-18-0330 |
0.311 |
|
| 2018 |
Wang JS, Barve MA, Chiorean EG, LoRusso P, Courtney KD, Qi D, Olguin A, Bullington J, Sardone M, Dunn V, Shemesh S, Chen J, Brooks C, Bauer TM. Interim results from a phase 1 trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology. 36: 2560-2560. DOI: 10.1200/Jco.2018.36.15_Suppl.2560 |
0.353 |
|
| 2017 |
Tumati V, Jackson WC, Abugharib AE, Raj G, Roehrborn C, Lotan Y, Courtney K, Bagrodia A, Gahan JC, Zumsteg ZS, Folkert MR, Laine AM, Hannan R, Spratt DE, Desai NB. Natural History of 'Second' Biochemical Failure Following Salvage Radiation Therapy for Prostate Cancer: A Multi-Institution Study. Bju International. PMID 28581200 DOI: 10.1111/Bju.13926 |
0.301 |
|
| 2017 |
Li J, Alyamani M, Zhang A, Chang KH, Berk M, Li Z, Zhu Z, Petro M, Magi-Galluzzi C, Taplin ME, Garcia JA, Courtney K, Klein EA, Sharifi N. Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer. Elife. 6. PMID 28191869 DOI: 10.7554/Elife.20183 |
0.34 |
|
| 2017 |
Sharifi N, Li J, Alyamani M, Zhang A, Chang K, Berk M, Li Z, Zhu Z, Petro M, Taplin M, Garcia JA, Courtney KD, Klein EA. Aberrant tumor metabolism to enable glucocorticoid receptor takeover in enzalutamide-resistant prostate cancer. Journal of Clinical Oncology. 35: 157-157. DOI: 10.1200/Jco.2017.35.6_Suppl.157 |
0.324 |
|
| 2017 |
Kobayashi M, Chung J, Beg M, Arriaga Y, Verma U, Courtney K, Mansour J, Haley B, Khan S, Horiuchi Y, Harker D, Gopal P, Cruz PD, Ariizumi K. Abstract 3660: Blocking the DC-HIL receptor reverses the T-cell suppression induced by proliferating myeloid-derived suppressor cells in common cancer types Cancer Research. 77: 3660-3660. DOI: 10.1158/1538-7445.Am2017-3660 |
0.328 |
|
| 2016 |
Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P, Hao G, Yousuf Q, Joyce A, Pedrosa I, Geiger H, ... ... Courtney K, et al. Targeting Renal Cell Carcinoma with a HIF-2 antagonist. Nature. PMID 27595394 DOI: 10.1038/Nature19796 |
0.32 |
|
| 2016 |
Li J, Alyamani M, Zhang A, Chang K, Berk M, Li Z, Zhu Z, Petro M, Magi-Galluzzi C, Taplin M, Garcia JA, Courtney K, Klein EA, Sharifi N. Author response: Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer Elife. DOI: 10.7554/Elife.20183.013 |
0.348 |
|
| 2015 |
Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, Priolo C, Kantoff P, Taplin ME. A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clinical Genitourinary Cancer. 13: 113-23. PMID 25450031 DOI: 10.1016/J.Clgc.2014.08.007 |
0.304 |
|
| 2014 |
Westphal AJ, Anderson D, Butterworth AL, Frank DR, Lettieri R, Marchant W, Von Korff J, Zevin D, Ardizzone A, Campanile A, Capraro M, Courtney K, Criswell MN, Crumpler D, Cwik R, et al. Stardust Interstellar Preliminary Examination I: Identification of tracks in aerogel Meteoritics and Planetary Science. DOI: 10.1111/Maps.12168 |
0.451 |
|
| 2013 |
Emerling BM, Benes CH, Poulogiannis G, Bell EL, Courtney K, Liu H, Choo-Wing R, Bellinger G, Tsukazawa KS, Brown V, Signoretti S, Soltoff SP, Cantley LC. Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients. Proceedings of the National Academy of Sciences of the United States of America. 110: 3483-8. PMID 23378636 DOI: 10.1073/Pnas.1222435110 |
0.554 |
|
| 2013 |
Emerling BM, Benes C, Bell E, Poulogiannis G, Courtney K, Lui H, Choo-Wing R, Bellinger G, Soltoff S, Cantley L. Abstract 4588: Identification of CDCP1 as a HIF-2α target gene involved in the regulation of cancer cell migration and metastasis. Cancer Research. 73: 4588-4588. DOI: 10.1158/1538-7445.Am2013-4588 |
0.546 |
|
| 2012 |
Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. Bju International. 110: 1729-35. PMID 22928480 DOI: 10.1111/J.1464-410X.2012.11456.X |
0.373 |
|
| 2012 |
Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, Hong BS, Tempel W, Dimov S, Shen M, Jha A, Yang H, Mattaini KR, Metallo CM, Fiske BP, Courtney KD, et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nature Chemical Biology. 8: 839-47. PMID 22922757 DOI: 10.1038/Nchembio.1060 |
0.635 |
|
| 2012 |
Patnaik A, Courtney K, Robichaud K, Bellinger G, Nardella C, Signoretti S, Wooster R, Pandolfi PP, Cantley L. Abstract LB-365: Effective use of PI3K/MTOR and MEK inhibitors prior to hormone ablative therapy in PTEN-loss driven murine prostate cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-365 |
0.519 |
|
| 2012 |
Anastasiou D, Yu Y, Israelsen WJ, Jiang J, Boxer MB, Hong BS, Tempel W, Dimov S, Shen M, Jha A, Yang H, Mattaini KR, Metallo CM, Fiske BP, Courtney KD, et al. Erratum: Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis Nature Chemical Biology. 8: 1008-1008. DOI: 10.1038/Nchembio1212-1008B |
0.47 |
|
| 2011 |
Patnaik A, Courtney K, Bellinger G, Lunsford E, Robichaud K, Grant A, Lenkinski R, Pedrosa I, Signoretti S, Wooster R, Cantley L. Abstract LB-418: Targeting the PI3K/mTOR pathway in genetically engineered mouse models of prostate cancer Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-418 |
0.511 |
|
| 2010 |
Courtney KD, Choueiri TK. Updates on novel therapies for metastatic renal cell carcinoma. Therapeutic Advances in Medical Oncology. 2: 209-19. PMID 21789135 DOI: 10.1177/1758834010361470 |
0.33 |
|
| 2010 |
Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1075-83. PMID 20085938 DOI: 10.1200/Jco.2009.25.3641 |
0.393 |
|
| 2009 |
Courtney KD, Choueiri TK. Optimizing recent advances in metastatic renal cell carcinoma. Current Oncology Reports. 11: 218-26. PMID 19336014 DOI: 10.1007/S11912-009-0031-5 |
0.342 |
|
| 2008 |
Shaywitz AJ, Courtney KD, Patnaik A, Cantley LC. PI3K enters beta-testing. Cell Metabolism. 8: 179-81. PMID 18762017 DOI: 10.1016/J.Cmet.2008.08.011 |
0.47 |
|
| 2001 |
Stradal T, Courtney KD, Rottner K, Hahne P, Small JV, Pendergast AM. The Abl interactor proteins localize to sites of actin polymerization at the tips of lamellipodia and filopodia. Current Biology : Cb. 11: 891-5. PMID 11516653 DOI: 10.1016/S0960-9822(01)00239-1 |
0.608 |
|
| 2000 |
Courtney KD, Grove M, Vandongen H, Vandongen A, LaMantia AS, Pendergast AM. Localization and phosphorylation of Abl-interactor proteins, Abi-1 and Abi-2, in the developing nervous system. Molecular and Cellular Neurosciences. 16: 244-57. PMID 10995551 DOI: 10.1006/Mcne.2000.0865 |
0.616 |
|
| 2000 |
Quackenbush RC, Reuther GW, Miller JP, Courtney KD, Pear WS, Pendergast AM. Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases. Blood. 95: 2913-21. PMID 10779439 |
0.597 |
|
| 2000 |
Quackenbush RC, Reuther GW, Miller JP, Courtney KD, Pear WS, Pendergast AM. Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases Blood. 95: 2913-2921. DOI: 10.1182/Blood.V95.9.2913.009K32_2913_2921 |
0.695 |
|
| 1998 |
Dai Z, Quackenbush RC, Courtney KD, Grove M, Cortez D, Reuther GW, Pendergast AM. Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway. Genes & Development. 12: 1415-24. PMID 9585502 DOI: 10.1101/Gad.12.10.1415 |
0.704 |
|
| Show low-probability matches. |
